Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review

References

• Melmed S, Bronstein M, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561.
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–3202.
   PubMed Web of Science ®Google Scholar
• Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294–302.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–248.
   PubMed Web of Science ®Google Scholar
• Moore D, Meads C, Roberts L, et al. The effectiveness and cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Birmingham: West Midlands Health Technology Assessment Collaboration (WMHTAC). DPHE Report No. 37; 2002.
   Google Scholar
• Connock M, Adi Y, Bayliss S, et al. The clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK73672/
   Google Scholar
• van Mastrigt GA, Hiligsmann M, Arts JJ, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704. doi:10.1080/14737167.2016.1246960
   PubMed Web of Science ®Google Scholar
• Einarson T, Acs A, Ludwig C, et al. Economic burden of cardiovascular disease in Type 2 Diabetes: a systematic review. Value Health. 2018;21(7):881–890.
   PubMed Web of Science ®Google Scholar
• van Mastrigt G, Hiligsmann M, Arts J, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–245.
   PubMed Web of Science ®Google Scholar
• Walker DG, Wilson RF, Sharma R, et al. Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK114550/
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta- analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Shin JL, Ezzat S. Cost-effectiveness of acromegaly treatments. Value Health. 1999;2(5):369.
   Google Scholar
• Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract. 2001;7(3):170–180.
   PubMedGoogle Scholar
• Didoni G, Grottoli S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004;27(11):1034–1039. doi:10.1007/BF03345306
   PubMed Web of Science ®Google Scholar
• Abrams P, Alexopoulou O, Abs R, et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol. 2007;157(5):571–577.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Paramo C, Varela da Costa C, et al. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest. 2007;30(7):541–545.
   PubMed Web of Science ®Google Scholar
• Valentim J, Passos V, Mataveli F, et al. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metab. 2008;52(9):1452–1460.
   PubMedGoogle Scholar
• Salinas Escudero G, Idrovo J, Rivas R, et al. Economic evaluation of long-term somatostatin analogs in the treatment of acromegaly in Mexico: monotherapy vs sequential therapy. Value Health. 2009; Rio Abstracts, A506.
   Google Scholar
• Biermasz NR, Roelfsema F, Pereira A, et al. Cost–effectiveness of lanreotide Autogel® in treatment algorithms of acromegaly. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(3):223–234.
   PubMedGoogle Scholar
• Moore D, Adi Y, Connock MJ, et al. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord. 2009;9(1):20.
   PubMedGoogle Scholar
• Fujii RK, Mould JF, Fernandes RA, et al. Economic evaluation of pegvisomant for active acromegaly patients who failed available therapies in Brazil – Public health care system perspective. Value Health. 2012;15(4):A105.
   Web of Science ®Google Scholar
• Alfonso-Cristancho R, Herran Diazgranados S, Maestre Martinez K, et al. Cost-effectiveness of somatostatin analogues for the treatment of acromegaly in Colombia. OJEMD. 2012;2(4):102–106.
   Google Scholar
• Roset M, Merino-Montero S, Luque-Ramírez M, et al. Cost of clinical management of acromegaly in Spain. Clin Drug Investig. 2012;32(4):235–245.
   PubMed Web of Science ®Google Scholar
• Tasdemir E, Magestro M, Griner BP, et al. Prevalence-based measurement of the economic burden of rare diseases: case review to determine the annual cost of acromegaly in France. Value Health. 2014;17(7):A527.
   PubMed Web of Science ®Google Scholar
• Kousoulakou K, Panayiotou-Pazaitou E, Pantazi C, et al. Economic evaluation of lanreotide autogel in the management of acromegaly in Greece. Value Health. 2014;17(7):A348–A349.
   PubMed Web of Science ®Google Scholar
• Tasdemir E, Magestro M, Griner BP, et al. Prevalence-based measurement of the economic burden of rare diseases: case review to determine the annual cost of acromegaly in Italy. Value Health. 2014;17:A323–A686.
   Web of Science ®Google Scholar
• Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333–341.
   PubMed Web of Science ®Google Scholar
• Ferreira CN, Rufino C, Santana CF. Acromegaly patients with inadequate response to maximum dose octreotide-lar who progress to treatment with pegvisomant: economic evaluation and incremental budget impact analysis from the public perspective to São Paulo State. Value Health. 2015;18(7):A842–A881.
   PubMed Web of Science ®Google Scholar
• Hahl J, Kurki S, Miettinen T, et al. Cost-effectiveness of pasireotide long-acting in a treatment of acromegaly in Finland. Economic evaluation based on Finnish Auria Biobank Data on health care resource utilization. Value Health. 2015;18:A335–A766.
   Web of Science ®Google Scholar
• Margusino-Framiñán L, Pertega-Diaz S, Pena-Bello L, et al. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. Eur J Intern Med. 2015;26(9):736–741.
   PubMed Web of Science ®Google Scholar
• Placzek H, Xu Y, Mu Y, et al. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. JMCP. 2015;21(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Chuang CC, Bhurke S, Chen SY, et al. Treatment patterns and economic burden in patients treated for acromegaly in the USA. Drugs Real World Outcomes. 2015;2(3):299–309.
   PubMedGoogle Scholar
• Sliwczynski A, Brzozowska M, Labenda A, et al. Real-world comorbidities, treatment pattern and cost of patients with acromegaly in Poland based on retrospective analysis of administrative claims data. Value Health. 2016;19(7):A347–A766.
   Web of Science ®Google Scholar
• Carlqvist P, Wilen-Koort A. A Cost-effectiveness analysis of pasireotide long-acting compared to continued use of a first-line somatostatin antagonist for the treatment of acromegaly in Sweden. Value Health. 2016;19(7):A591.
   Web of Science ®Google Scholar
• Lesén E, Granfeldt D, Houchard A, et al. Cost-of-illness of acromegaly in Sweden – A register-linkage population-based study. Value Health. 2016;19(7):A669.
   Web of Science ®Google Scholar
• Xuan JW, Zhang ZY, Wang YF, et al. Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China. Zhonghua Yi Xue Za Zhi. 2017;97(10):765–769.
   PubMedGoogle Scholar
• Elbaum M, Bolanowski M. One-center analysis of cost associated with acromegaly management in Poland. Value Health. 2017;20(9):A477.
   Web of Science ®Google Scholar
• Kamusheva M, Zaharieva S, Elenkova A, et al. Health-related quality of life and pharmacotherapy costs study for patients with rare endocrine diseases in Bulgaria – A pilot study. Value Health. 2017;20(9):A560.
   Web of Science ®Google Scholar
• Peral C, Cordido F, Gimeno V, et al. Cost-effectiveness analysis of second-line pharmacological treatments of acromegaly in Spain. Value Health. 2017;20(9):A557.
   Web of Science ®Google Scholar
• Liu S, Adelman DT, Xu Y, et al. Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med. 2018;66(3):653–660.
   PubMed Web of Science ®Google Scholar
• Rusenova Y, Alimanova B, Marinova D, et al. Pharmacotherapy costs for patients with acromegaly in bulgaria. Value Health. 2018;21(3):S451.
   Google Scholar
• Korkmaz O, Gurcan M, Nuhoglu Kantarci FE, et al. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly. Pituitary. 2019;22(4):387–396.
   PubMed Web of Science ®Google Scholar
• Leonart LP, Borba HHL, Ferreira VL, et al. Cost-effectiveness of acromegaly treatments: a systematic review. Pituitary. 2018;21(6):642. doi:10.1007/s11102-018-0908-0
   PubMed Web of Science ®Google Scholar